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Abstract
Background: Atherosclerosis (AS) is a common cardiovascular disease. Transformation of macrophages to form
foam cells by internalizing modified low density-lipoprotein (LDL) via scavenger receptor (SR) is a key pathogenic
process in the onset of AS. It has been demonstrated that SR-PSOX functions as either a scavenger receptor for
uptake of atherogenic lipoproteins and bacteria or a membrane-anchored chemokine for adhesion of
macrophages and T-cells to the endothelium. Therefore, SR-PSOX plays an important role in the development of
AS. In this study the key basic amino acids in the chemokine domain of SR-PSOX have been identified for its
functions.
Results: A cell model to study the functions of SR-PSOX was successfully established. Based on the cell model, a
series of mutants of human SR-PSOX were constructed by replacing the single basic amino acid residue in the
non-conservative region of the chemokine domain (arginine 62, arginine 78, histidine 80, arginine 82, histidine 85,
lysine 105, lysine 119, histidine 123) with alanine (designated as R62A, R78A, H80A, R82A, H85A, K105A, K119A and
H123A, respectively). Functional studies showed that the mutants with H80A, H85A, and K105A significantly
increased the activities of oxLDL uptake and bacterial phagocytosis compared with the wild-type SR-PSOX. In
addition, we have also found that mutagenesis of either of those amino acids strongly reduced the adhesive
activity of SR-PSOX by using a highly non-overlapping set of basic amino acid residues.
Conclusion: Our study demonstrates that basic amino acid residues in the non-conservative region of the
chemokine domain of SR-PSOX are critical for its functions. Mutation of H80, H85, and K105 is responsible for
increasing SR-PSOX binding with oxLDL and bacteria. All the basic amino acids in this region are important in the
cells adhesion via SR-PSOX. These findings suggest that mutagenesis of the basic amino acids in the chemokine
domain of SR-PSOX may contribute to atherogenesis.
Background
Atherosclerosis (AS) is a common cardiovascular disease
that threatens human health. The pathological features
of AS include infiltration of monocytes, formation of
foam cells and proliferation of smooth muscle cells
[1-4]. The first macroscopically recognizable lesion of
atherosclerosis arises from the accumulation of macro-
phage-derived foam cells with cholesterylester-rich lipid
droplets [5]. A high level of plasma concentration of
low-density lipoprotein (LDL) is an important risk factor
for atherosclerosis. When LDL molecules are trapped in
an arterial wall, they are modified or oxidized and inter-
nalized by macrophage via a relatively large family of
scavenger receptors (SR) [6-8] including scavenger
receptor class A (SR-A), CD36 [9], CD68 [10], the lec-
tin-like oxLDL receptor [11] and scavenger receptor for
phosphatidylserine and oxidized lipoprotein (SR-PSOX)
[12]. Monocytes/macrophages engulf oxLDL via the sca-
venger receptors on the cell surface to foam cells with-
out negative feedback [13].
The scavenger receptor SR-PSOX was firstly discov-
ered by Shimaoka research group in 2000 [14]. Further
studies show that the protein of SR-PSOX exists in
either a membrane-bound or a soluble form. SR-PSOX
in the membrane-bound form is a type I transmembrane
glycoprotein with 254-amino acids, consisting of CXC
chemokine, mucin stalk, transmembrane and cytoplas-
mic domains [15]. The soluble form of SR-PSOX, which
serves as a chemokine CXCL16, is generated from its
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[16-20]. The membrane form of SR-PSOX can bind and
internalize oxLDL and phosphatidylserine, not native or
acetylated LDL [14]. Similar to several other scavenger
receptors, SR-PSOX is able to mediate adhesion and
phagocytosis of Gram negative and positive bacteria by
professional antigen-presenting cells [21,22]. Recently a
study has showed that CXCL16
-/- LDLR
-/- mice develop
larger atherosclerotic lesions, when compared with
LDLR
-/- mice, which is expected to be atheroprotective
[23]. More interestingly, Lehrke et al. has reported that
patients with coronary artery disease (CAD) have a
higher level of SR-PSOX [24] although Lieshout et al.
indicates that the level of SR-PSOX in serum is not
associated with the severity of CAD [25]. Obviously the
relevance of the serum SR-PSOX and CAD needs to be
further investigated.
SR-PSOX is the first scavenger receptor that has been
identified as a chemokine [14]. The extracellular part of
SR-PSOX consists of two distinct domains: the CXC
chemokine domain and the mucin stalk domain. Shi-
maoka et al. have shown that only the chemokine
domain of SR-PSOX is required for the recognition of
bacteria and binding of oxLDL, however, bacterial pha-
gocytosis via SR-PSOX is inhibited by oxLDL [21]. In
addition, the replacement of some conserved basic
amino acid residues in the chemokine domain of SR-
PSOX with alanine significantly impaired the activities
of bacterial phagocytosis, oxLDL uptake and the chemo-
taxis of CXCR6-expressing cells [26]. To examine
whether the nonconservative basic amino acids in the
chemokine domain are critical for the function of SR-
PSOX, we generated a series of mutants of human SR-
PSOX by replacing a single basic amino acid residue in
the chemokine domain with alanine. Furthermore, we
overexpressed these mutants in 293T cells and subse-
quently examined the uptake of oxLDL, phagocytosis of
bacteria and adhesive activity. In this report, we demon-
strate that the basic amino acids in the nonconservative
region of the chemokine domain play a central role in
the uptake of oxLDL, phagocytosis of bacteria and adhe-
sive activity of SR-PSOX. Our findings provide new
insight into the structure and function of SR-PSOX and
t h ei n f o r m a t i o nm a yb eu s e f u lf o rt h ed e v e l o p m e n to f
drug target of atherosclerosis.
Materials and methods
Plasmid pEGFP-N3 was purchased from Clontech
Laboratories (Mountain View, CA, USA). Restriction
enzymes EcoR I and BamH I, and T4 DNA ligase were
obtained from Fermentas (USA). Plasmid DNA purifica-
tion kits were purchased from Omega (USA). Trizol
reagent and Alexa Fluor 594-labeled E.coli were pur-
chased from Invitrogen (USA). DiI-oxLDL was obtained
from Kalen Biomedical (USA). Goat anti-human SR-
PSOX antibody and APC-labeled rat anti-human SR-
PSOX antibody were obtained from R&D (USA).
Cell culture
The human monocyte cell line THP-1 (Shanghai Insti-
tute of Cell Biology, Chinese Academy of Sciences,
Shanghai, China) was grown in RPMI 1640 medium
supplemented with 10% FBS, 100 μg/mL of streptomy-
cin and 100 U/mL of penicillin. The human embryonic
kidney cell line 293T (Shanghai Institute of Cell Biology,
Chinese Academy of Sciences, Shanghai, China) was cul-
tured in high glucose DMEM containing10% FBS, 100
μg/mL of streptomycin and 100 U/mL of penicillin. All
the cells were maintained in a humidified 5% CO2 atmo-
sphere at 37 °C. The medium was replaced every 2-3
days during the time of culture.
Generation of SR-PSOX expression vectors
THP-1 cells were stimulated by 100nM PMA for 24
hours and the total RNA was extracted by Trizol
reagent according to the instructions of the producer.
Human SR-PSOX (GenBank accession number
NM_022059) open frame was amplified by PCR from
cDNA generated by reverse transcription of mRNA. The
forward primers included a restriction site for EcoR I
was 5’-CCG GAA TTC ATG TCT GGG AGT-3’.T h e
reverse primer included a restriction site for BamH I
was 5’-CGC GGA TCC GGT ATT AGA GTC-3’.T h e
PCR product was cloned into the expression vector
pEGFP-N3 (Invitrogen). The correct clone was con-
firmed by sequencing.
Site-directed mutagenesis of SR-PSOX
The mutants of SR-PSOX were generated by the over-
lapping-extension PCR method. The technique was
based on two rounds of PCR amplifications using two
different flanking regions and two internal primers
designed to generate the desired mutations. During the
first PCR round, the internal primers and flanking pri-
mers were used to generate double stranded portions of
the target DNA sequence that contains the desired
mutations. During the second PCR round, those double-
stranded DNA fragments and flanking primers were uti-
lized to generate a mutated product corresponding to
the total length of the target sequence. All mutations of
SR-PSOX in the study used were performed with the
above approach. All the primers needed were designed
by Primer Premier 5.0 software. The specific primer
pairs used for the mutagenesis were as follows (small
letters represent mutational nucleotides): R62A, 5’-CGG
AAG AAA TTg cTT TAC CAC AAT-3’ and 5’-ATT
GTG GTA AAg cAA TTT CTT CCG-3’; R78A, 5’-CTC
AGG TGT TTa gcG AGA CGA TTC AT-3’ and 5’-
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H80A, 5’- GTA AGC TCT CAG Agc TTT CCG GAG
AC -3’ and 5’- GTC TCC GGA AAg cTC TGA GAG
CTT AC -3’; R82A, 5’- GAT GGT AAG CTg cCA GGT
GTT TCC -3’ and 5’- GGA AAC ACC TGg cAG CTT
ACC ATC -3’;H 8 5 A ,5 ’- GTA TAG ACA CCG Agc
GTA AGC TCT CAG -3’ and 5’- CTG AGA GCT TAC
gcT CGG TGT CTA TAC -3’; K105A, 5’- ACC CAT
GGG TCa gcG TTG CCC CCA C -3’ and 5’-G T G
GGG GCA ACg ctG ACC CAT GGG T -3’; K119A, 5’-
GTC CAC ATT CTg cGA GAT CAA GAC -3’ and 5’-
GTC TTG ATC TCg cAG AAT GTG GAC -3’;H 1 2 3 A ,
5’- CCG AGT AAG CAg cTC CAC ATT CTT -3’ and
5’- AAG AAT GTG Gag cTG CTT ACT CGG -3’.
PCRs were performed using pfuDNA polymerase (Tian-
gen Biotech, China) according to the manufacturer’s
protocol. The mutants of SR-PSOX were cloned into
the expression vector pEGFP-N3. The correct mutations
of SR-PSOX were confirmed by sequencing.
Transfection of SR-PSOX recombinant plasmids
293T cells were seeded on coverslips and cultured in
24-well plates in DMEM medium overnight to allow
cells to grow to 60-70% confluence at the time of trans-
fection. For the transfection, U-fectin Transfection Kit
(Plurigen, China) was used according to the manufac-
turer’s instructions. Briefly, 0.5 μg DNA of SR-PSOX
recombinant plasmid was diluted in 50 μl RPM1640
medium. 1.5 μl U-fectin was diluted in 25 μlU - f e c t i n
buffer mixed with 50 μl diluted DNA solution, and incu-
bated for 20 minutes at room temperature. The mixture
was then added to the well with 0.5 ml of fresh DMEM
medium. The transfected cells were cultured for 24
hours before carrying further experiments.
Analysis of SR-PSOX protein expression by flow
cytometry
Transfected cells were harvest into FACS tubes by using
0.5 mM EDTA, and washed twice with FACS buffer (1
× PBS containing 5% FBS and 0.01%NaN3). Cells were
incubated with APC-labeled rat anti-human SR-PSOX
antibody for 40 minutes at 4°C after cells were blocked
with mouse serum, followed by washing twice with
FACS buffer. Stained cells were assayed by Flow Cyto-
metry (BD Calibur, USA) after adding FACS fixed buffer
(FACS buffer containing 1% paraformaldehyde).
Analysis of SR-PSOX protein expression by fluorescence
microscopy
Cells were cultured on coverslips after 24 hours trans-
fection and then fixed with 4% paraformaldehyde for 20
minutes at room temperature. After fixation, cells were
blocked with PBST (containing 1% bovine serum
albumin and 0.3M glycine) for 30 minutes at room tem-
perature. Cells were then washed with PBS and incu-
bated with the goat anti-human SR-PSOX antibody
(diluted in 1% bovine serum albumin/PBST) overnight
at 4°C, followed by washing with PBST. Cells were then
incubated with Cy3-labeled donkey anti-goat secondary
antibody (Beyotime, China) for 1 hour at room tempera-
ture in dark. After washing, the cells on coverslides were
mounted in glycerol and sealed with nail polish. Evalua-
tion of SR-PSOX expression on the surface of cell was
performed by Confocal Microscope (Leica TCS SP5X
Microsystems, Germany).
Uptake of oxLDL
Transfected cells were assayed for oxLDL uptaking. The
culture medium was replaced with 250 μlf r e s hc u l t u r e
medium DMEM in each well and cells were incubated
with 20 μg/ml Dil-oxLDL for 4 hours at 37°C. Cells
were then washed twice with PBS and collected into
FACS tubes with 0.25% trypsin. The cells were assayed
by Flow Cytometry after washing twice with FACS
buffer.
Phagocytosis of bacteria
Transfected cells were incubated with Alexa Fluor 594-
labeled E.coli (3 × 10
6 cells/ml) for 4 hours at 37°C.
Cells were then washed with FACS buffer and detached
with trypsin. The cells were collected into FACS tubes
and washed twice with FACS buffer again. The number
of cells internalized with Alexa Fluor 594-labeled bac-
teria was quantified by Flow Cytometry.
Assays of cell adhesion
Transfected cells were washed with PBS before incubat-
ing with 0.5M EDTA for 10 minutes at 37°C. Cells were
then washed again with PBS and fixed with 4% parafor-
maldehyde for 15 minutes. Being washed with distilled
water, cells were stained with 0.1% crystal violet staining
solution for 20 minutes at room temperature. The cells
were washed again and allowed to air dry before cells
were incubated with 10% acetic acid for 20 minutes
with shaking. The OD values for crystal violet staining
were measured at 595 nm by Microplate Reader (ELX
800 Bio Tek, USA).
Statistical analysis
All experiments were repeated at least three times
respectively. The data shown in all figures are expressed
as the mean ± SEM of values from independent experi-
ments. The paired Student-t test was used to evaluate
the statistical significance of differences between experi-
mental groups. Samples with P < 0.05 were considered
significantly different.
Liu et al. Lipids in Health and Disease 2011, 10:59
http://www.lipidworld.com/content/10/1/59
Page 3 of 8Results
Expression of wild-type SR-PSOX and mutants in 293T
Cells
The scavenger receptor SR-PSOX is a 30 kDa type I
transmembrane glycoprotein. The coding sequence of
SR-PSOX (837 bp) was subcloned into pEGFP-N3 vec-
tor (Figure 1). All the SR-PSOX mutants were con-
structed as described in materials and methods, and
confirmed by sequencing. To verify if recombinant plas-
mid pEGFP-N3-SR-PSOX could be normally expressed
on the surface of cells, a pEGFP-N3 empty vector and
pEGFP-N3-SR-PSOX were transfected into 293T cells
respectively. After 24 hours transfection, the cells were
stained with anti-SR-PSOX antibody, counter stained
with a Cy3-conjugated secondary antibody, and the
images were then directly viewed under a fluorescent
microscope. As shown in Figure 2, EGFP was well
expressed in the cells transfected with either of the
recombinant plasmids. As expected, SR-PSOX was
expressed on the plasma membranes.
Shimaoka et al. first showed that conserved basic
amino acids in the chemokine domain of SR-PSOX are
critical for the cells migration, phagocytosis and ox-LDL
uptake [26]. To examine whether the non-conservative
basic amino acids in the chemokine domain of SR-
PSOX are the recognition sites of SR-PSOX for bacteria,
oxLDL and adhesive activity, several basic amino acids
of human SR-PSOX in the chemokine domain were
selected with the help of bioinformatics for mutagenesis.
These basic amino acid residues, including arginine 62,
histidine 80, arginine 82, histidine 85, lysine 105, lysine
119 and histidine 123, located in the non-conservative
region of the chemokine domain in human SR-PSOX
were replaced with alanine (designated as R62A, H80A,
R82A, H85A, K105A, K119A and H123A, respectively).
Arginine 78 (R78A) was set as a control (reported as
R59A in Ref. 26). SR-PSOX wide-type and mutant con-
structs were transiently transfected into 293T cells and
the expressing level of the proteins in the cells was
determined by FACS analysis (Additional file 1: Figure
S1). Obviously the SR-PSOX proteins were evenly
expressed on the surface of the cells as determined by
flow cytometry analysis after immunostaining (Figure 3).
Replacements of basic amino acid residues in SR-PSOX
alter DiI-oxLDL uptake in the transfected 293T Cells
Since oxLDL is a ligand for SR-PSOX, replacement of
certain amino acid in the non-conservative region of the
chemokine domain of SR-PSOX may result in altering
its capability to oxLDL uptake. To test the hypothesis,
293T cells were transfected with SR-PSOX wide-type
and mutant plasmids. After transfection for 24 hours,
the cells were incubated with Dil-oxLDL and the uptake
of DiI-oxLDL in the cells was analysed by FACS (Addi-
tional file 2: Figure S2). As shown in Figure 4, the
uptake of DiI-oxLDL by H80A, H85A and K105A
mutant-expressed cells was increased by 58%, 96% and
72% respectively compared with that of wild-type SR-
PSOX, and the enhancements were statistically signifi-
cant. However, the cells expressing other mutants only
slightly increased the uptake of DiI-oxLDL, suggesting
that mutation of H80, H85 and K105 is very important
for the cell to absorb oxLDL. These results implicate
that mutagenesis of the basic amino acid in the non-
conservative region of the chemokine domain may con-
tribute to the atherogenic process.
Activities of bacterial phagocytosis could be changed by
replacements of basic amino acid residues in SR-PSOX
SR-PSOX plays an important role in facilitating uptake
of various pathogens by APCs through its chemokine
domain [27]. To determine whether mutation of any
basic amino acid in the non-conservative region of the
chemokine domain impacts phagocytosis of the cells,
293T cells transfected with wild-type and mutant types
of SR-PSOX were incubated with Alexa Fluor 594-
labeled E. coli. and internalized bacteria in the cells
were quantified by FACS (Additional file 3: Figure S3).
Interestingly the phagocytotic activity of the cells
expressing H80A, H85A and K105A mutant was
remarkably increased when compared with the cells
expressing wild-type SR-PSOX (Figure 5). Taken
together, our results suggest that H80, H85 and K105
may be necessary for SR-PSOX to function as a gate
guard to prevent foreign molecules from getting into a
cell.
Figure 1 Construction of SR-PSOX fragment into pEGFP-N3
expression vector. Constructed products were analysed by 1%
agarose gel to confirm the right size of fragment. Lane 1, empty
pEGFP-N3 vector only (4700bp). Lane 2, wild type of SR-PSOX
fragment was inserted in to the vector as pEGFP-N3-SR-PSOX
construct (5541bp). Lane 3, pEGFP-N3-SR-PSOX construct was
digested with EcoR I and BamH I to form the right size of two
bands (4700bp and 841bp). Lane 4, the right size of full-length of
SR-PSOX fragment was amplified after PCR reaction. M, DNA ladder.
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could reduce the adhesive activity in the transfected 293T
cells
To examine whether these basic amino acids are
important in the non-conservative region of the SR-
PSOX chemokine domain for the adhesive activity of
cells, 293T cells expressing wild type and mutants of
SR-PSOX were incubated in the presence or absence
of EDTA for 10 minutes at 37 °C, and the adhesion
cells were quantified by crystal violet stain. To our sur-
prise, the cells expressing all the SR-PSOX mutants
Figure 2 The transfected 293T cells were expressing pEGFP and SR-PSOX proteins detected by confocal microscopy. 293T cells were
transiently transfected with pEGFP-N3 empty vector or pEGFP-N3-SR-PSOX construct (wild-type SR-PSOX cloned into pEGFP-N3 vector) for 24
hours respectively. The fluorescence images of the cells were observed under confocal microscope after the cells were immunostained with
APC-labeled rat anti-human SR-PSOX antibody. Top panel (vector), the cells were transfected with pEGFP-N3 empty vector alone. Bottom panel
(wild type), the cells were transfected with pEGFP-N3-SR-PSOX construct.
Figure 3 Expression levels of SR-PSOX on the surface of
transfected 293T cells. 293T cells were transiently transfected with
pEGFP-N3 empty vector, wild-type SR-PSOX and different mutant
constructs respectively. After 24 hours transfection, the cells were
harvested and stained with APC-labeled anti-SR-PSOX antibody. The
expression levels of SR-POSX on the surface of the cells in each
group were measured by FACS. The data are represented as the
mean ± SEM by the percentage of SR-PSOX-positive cells in the
EGFP-positive cells from three independent experiments.
Figure 4 Uptake of DiI-oxLDL by the transfected 293T cells.
293T cells were transiently transfected with pEGFP-N3 empty vector,
wild-type SR-PSOX and different mutant constructs respectively.
After 24 hours transfection, cells were incubated with DiI-oxLDL for
4 hours at 37°C. The relative intensity of red fluorescence represents
the ability of DiI-oxLDL uptaked by the cells. The results show the
mean ± SEM of the intensity of red fluorescence in the EGFP-
positive 293T cells from three independent experiments. *: P < 0.05,
**: P < 0.01, each compared to the wild-type SR-PSOX (WT).
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H123A) showed significant reduction of adhesive activ-
ities when compared with the cells expressing wild-
type SR-PSOX. As shown in Figure 6, the highest
reduction of adhesive activity among these mutants
was about 58.5%. Thus, the results suggest that all of
the basic amino acid residues in the non-conservative
region of the SR-PSOX chemokine domain may be cri-
tical for cell adhesion.
Discussion
SR-PSOX functions as a membrane receptor for multi-
ple ligands including oxLDL, phosphatidylserine and
bacteria. On the other hand, the soluble form of SR-
PSOX, produced by proteolytic cleavage of the mem-
brane-bound form, is an interferon-gamma-regulated
chemokine CXCL16 [14,21,22]. Structurally, SR-PSOX
consists of CXC chemokine, mucin stalk, transmem-
brane and cytoplasmic domains [15]. Shimaoka et al.
have shown that the chemokine domain of SR-PSOX is
uniquely required for the recognition of bacteria and is
responsible for phagocytosis of macrophages. Interest-
ingly, it has been found that both bacteria and oxLDL
compete for binding of SR-PSOX [21]. In this study, we
have found that the basic amino acid residues at non-
conservative region in the chemokine domain are very
important for the function of SR-PSOX. Mutation of
these individual amino acids, in particular H80, H85 and
K105, resulted in significantly increasing the activities of
oxLDL uptake and bacterial phagocytosis. Interestingly,
mutagenesis analysis revealed that all of these amino
acids selected from in the non-conservative region of
the SR-PSOX chemokine domain are necessary for cell
adhesion. Clearly, our results provide a novel spectrum
about the structure and function of SR-PSOX.
CX3CL1 is another transmembrane chemokine with
similar functions as SR-PSOX. It has been reported that
both the chemotaxis and adhesion functions of the cells
overexpressing CX3CL1 are critically impaired by the
replacement of the basic amino acid residues in the che-
mokine domain of CX3CL1 with alanine [27]. Similarly,
Shimaoka et al. have also found that conversion of any
basic amino acid residue, in particular R59, R67 and
R73, with alanine in the conserve region of the chemo-
kine domain of SR-PSOX significantly reduced activities
of bacterial phagocytosis, oxLDL uptake and the chemo-
taxis of the cells expressing the mutants when compared
with wild-type SR-PSOX [26], suggesting that the indivi-
dual basic amino acid residue in the conserve region of
the chemokine domain of SR-PSOX is also important
for the recognition of oxLDL, bacteria and adhesion.
However, Shimaoka’s group has reported that the
mutant R78A did not significantly change the activities
in oxLDL uptake and bacterial phagocytosis, which is
controversial with our observation [26]. There are two
possibilities that may cause the difference: (1) FACS was
used in our study to detect the uptake of oxLDL while
Shimaoka’s group used fluorescence microscopy. The
FACS analysis is considered to be more sensitive than
microscopy analysis; (2) we incubated Alexa Fluor 594-
labeled E. coli for 4 hours at 37 °C while Shimaoka’s
group only incubated FITC-labeled E. coli for 1 hour at
37 °C. In our system, we hardly detected the
Figure 5 Phagocytosis of bacteria by the transfected 293T
cells. 293T cells were transiently transfected with pEGFP-N3 empty
vector, wild-type SR-PSOX and different mutant constructs
respectively. After 24 hours transfection, the cells were incubated
with Alexa Fluor 594-labeled E. coli for 4 hours at 37°C. The mean
values of phagoctosed bacterial are represented as the intensity of
Alexa Fluor 594 fluorescence in the EGFP-positive 293T cells. The
values are relative to the wild-type SR-PSOX group set as 100%. The
data show the mean ± SEM from four independent experiments. *:
P < 0.05, **: P < 0.01, each compared to wild-type SR-PSOX (WT).
Figure 6 Cells adhesion ability in the transfected 293T cells.
293T cells were transiently transfected with pEGFP-N3 empty vector,
wild-type SR-PSOX and different mutant constructs respectively.
After 24 hours transfection, the cells were incubated with EDTA for
10 minutes at 37°C. The number of adhesion cell was quantified by
crystal violet stain. OD value was used to measure the adhesive
ability on the cells. The data show the mean ± SEM from three
independent experiments. *: P < 0.05, **: P < 0.01, each compared
to wild-type SR-PSOX (WT).
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C. These indicated that phagocytosis effect is time
dependent.
The extracellular part of SR-POSX is composed of
chemokine domain and mucin domain. It has been
reported that CX3CR1 also has the two distinct domains
that critically influence cells adhesion [28]. Our results
are consistent with the observation. Taken together, it is
obvious that a highly non-overlapping set of basic
amino acid residues in the non-conservative region of
the chemokine domain are important for cell adhesion.
Conclusions
The cell model for studying the functions of SR-PSOX
has been successfully established in this study. The
results reveal that non-conservative basic amino acids in
the chemokine domain are critical for the functions of
SR-PSOX. Further studies will be needed to investigate
the occurrence of mutagenesis in these basic amino
acids in the clinical specimens, which may provide
direct evidence that mutation of a specific basic amino
acid in the non-conservative region of the chemokine
domain of SR-PSOX contributes to the development of
AS. The information obtained from this study may be
useful for the design of therapeutic agents that target
SR-PSOX for the treatment of AS.
Additional material
Additional File 1: Figure S1: Expression of SR-PSOX receptor on the
surface of transfected 293T cells. 293T cells were transiently
transfected with empty vector, wild-type SR-PSOX and different mutant
constructs respectively. After 24 hours transfection, the cells were
harvested and assayed. The cells were stained with APC-labeled anti-SR-
PSOX antibody, and SR-PSOX positive cells were then detected by FACS.
The data shown represent one typical experiment from three
independent experiments.
Additional File 2: Figure S2: Uptake of DiI-oxLDL by transfected
293T cells. 293T cells were transiently transfected with empty vector,
wild-type SR-PSOX and different mutant constructs respectively. After 24
hours transfection, the cells were incubated with DiI-oxLDL for 4 hours at
37 °C, and then DiI-oxLDL positive cells were measured by FACS. The
data shown represent one typical experiment from three independent
experiments
Additional File 3: Figure S3: Phagocytosis of bacteria by transfected
293T cells. 293T cells were transiently transfected with empty vector,
wild-type SR-PSOX and different mutant constructs respectively. After 24
hours transfection, the cells were incubated with Alexa Fluor 594-labeled
E. coli for 4 hours at 37°C, and the E. coli positive cells were counted by
FACS. The data shown represent one typical experiment from four
independent experiments.
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